
Currently Co-Director at the UROSALUD Clinic and Clinical Chief of prostate cancer at the IVO Foundation. Specialized in robotic and laparoscopic surgery and Prostatic Enucleation. Clinical Research in Prostate Cancer. Degree in Medicine from the University of Navarra (1996-2002), PhD from the University of Valencia (2010). MIR at Hospital Universitario la Fe Valencia (2003-2008), Fellow of Laparoscopic Radical Prostatectomy at University Clinic Leipzig with Prof Stolzenburg (2008-2009). Master in Molecular Oncology (CNIO and CEB), Master in Medical Direction and Clinical Management (UNED), Master in Health Management and Research (UNED). Member of the Valencian, Spanish and European Urology Associations. Storz Fellow at the International Endourological Society. Reviewer, moderator, speaker and surgeon of the European and National Urology Congresses since 2010. Assistant Urologist in the Laparoscopy Unit of the Hospital Universitario La Fe, Valencia (2009). Assistant Urologist and responsible for the implementation of pelvic laparoscopic surgery at the University Hospital of La Ribera (Alzira, Valencia).
Clinical and surgical stays and internships with world reference urologists in the centers: LEIPZIG UNIVERSITY HOSPITAL, UCL LONDON, HOMBURG-SAAL UNIVERSITY HOSPITAL (GERMANY) and MSKCC (NEW YORK). Instructor and teacher in several courses of laparoscopic surgery with live surgeries in national and international meetings. Author of a hundred scientific articles indexed in http://www.ncbi.nlm.nih.gov/pubmed/?term=ramirez+backhaus. More than 200 posters presented at national and international congresses.
Selected publications from PubMed
When evidence is not interchangeable: The limits of therapeutic equivalence in high-risk biochemical recurrence of prostate cancer.
Pérez Fentes D, Gómez Iturriaga A, Ramírez Backhaus M, Gómez Rivas J, López Campos F
Actas Urol Esp (Engl Ed). 2026 Sep;50(7):501989 doi: 10.1016/j.acuroe.2026.501989.
How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.
Freedland SJ, De Giorgi U, Rannikko A, Saad F, Gleave M, Ramírez Backhaus M, Mulhall J, Pandya BJ, Ivanova J, Kral P, Turnbull J, Shore N
Future Oncol. 2026 Jul;22(16):1899-1911 doi: 10.1080/14796694.2026.2691257.
External validation of the heidenreich criteria for patients with post-chemotherapy residual masses of non-seminomatous germ cell tumor.
Claps F, Ramírez-Backhaus M, Gómez-Ferrer Á, Mascarós JM, Collado Serra A, Wong A, Calatrava Fons A, Climent MÁ, Amodeo A, Porreca A, Rubio-Briones J
Can J Urol. 2026 Jun 26;33(3):593-602 doi: 10.32604/cju.2025.070162.
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.
Shore ND, De Giorgi U, Tutrone RF, Bailen JL, Roos EPM, Kliment J, Marx G, Karsh LI, Ramirez-Backhaus M, Uchio EM, Supiot S, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ
J Urol. 2026 Apr;215(4):396-407 doi: 10.1097/JU.0000000000004879.
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK.
De Giorgi U, Freedland SJ, Rannikko A, Ramirez-Backhaus M, Villers A, Tarazi J, Tang Y, Haas GP, Rosales M, Shore ND
Prostate Cancer Prostatic Dis. 2026 Mar;29(1):198-201 doi: 10.1038/s41391-025-00959-8.
Help your network discover Dr. Miguel Ramírez Backhaus's clinical expertise.